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Differential Cytokine Responses following Marek’s Disease Virus
Infection of Chickens Differing in Resistance to
Marek’s Disease
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The production of cytokine mRNAs, in addition to viral DNA, was quantified by real-time quantitative
reverse transcription-PCR (RT-PCR) (cytokines) or PCR (virus) in splenocytes during the course of Marek’s
disease virus (MDV) infection in four inbred chicken lines: two resistant (lines 61 and N) and two susceptible
(lines 72 and P). Virus loads were only different after 10 days postinfection (dpi), increasing in susceptible lines
and decreasing in resistant lines. Gamma interferon (IFN-) mRNA was expressed by splenocytes from all
infected birds between 3 and 10 dpi, associated with increasing MDV loads. For other cytokines, differences
between lines were only seen for interleukin-6 (IL-6) and IL-18, with splenocytes from susceptible birds
expressing high levels of both transcripts during the cytolytic phase of infection, whereas splenocytes from
resistant birds expressed neither transcript. These results indicate that these two cytokines could play a crucial
role in driving immune responses, which in resistant lines maintain MDV latency but in susceptible lines result
in lymphomas.
Marek’s disease virus (MDV) is a highly cell-associated,
lymphotropic alphaherpesvirus that causes Marek’s disease
(MD) in chickens. Clinical signs include immunosuppression,
polyneuritis, and T-cell lymphoma formation in the visceral
and ectoderm-derived tissues. Although MD has been con-
trolled by vaccination for over 30 years, it continues to be a
serious threat to the health and welfare of poultry, and there is
growing evidence that intensive use of vaccines is driving the
virus to increasing virulence (62). Infection with virulent
strains of serotype 1 MDV causes an early cytolytic infection (3
to 7 days postinfection [dpi]), primarily in B lymphocytes with
temporary, often profound, immunosuppression (14) and T-
cell activation. Once activated, T lymphocytes themselves be-
come susceptible to infection, which can be lytic, but after
about 7 dpi, the virus enters latency (54).
Mechanisms underpinning establishment and maintenance
of latency have not been elucidated, but are clearly influenced
by a complex set of interactions involving viral genes and the
host’s immune responses (15, 48). Cytokines have been impli-
cated in the maintenance of latency, especially alpha interferon
(IFN-) (59, 60) and a soluble latency-maintaining factor (12).
All chicken genotypes are susceptible to MDV infection, but
they differ greatly in their resistance or susceptibility to clinical
MD. Several genetic loci are involved (14). The chicken major
histocompatibility complex (MHC) has a strong influence on
MD resistance (7, 38). Genes within the class I (B-F) region
are most influential, with the B21 haplotype (line N) expressing
the lowest levels of class I but possessing the highest order of
resistance (29), whereas the B19 haplotype (line P) expresses
the highest levels of class I and represents the highest level of
susceptibility. Other forms of genetic resistance are associated
with genes outside of the MHC, the most notable examples
being lines 61 and 72, which are homozygous for the B2 hap-
lotype (14, 17). Line 61 is highly resistant, and line 72 is highly
susceptible to clinical MD (32). MD resistance in these lines
has been mapped to genetic loci outside of the MHC, most
importantly a cluster of genes (MDV1 locus) on chicken chro-
mosome 1 (9). This region has synteny with the mammalian
lectin-like natural killer (NK) cell antigen complex (31, 65)
that contains the Cmv1 locus for resistance to murine cytomeg-
alovirus (8, 33, 47). The outcome of MDV infection is associ-
ated with MDV load during the early stages of infection, a
significant association between viral load in peripheral blood
leukocytes and the development of clinical MD being evident
as early as 4 dpi (10).
Until recently the role of cytokines in the pathogenicity of
and immune responses to MD has been poorly understood.
Xing and Schat (63, 64) investigated the effects of MDV in-
fection on transcription of a number of cytokines, both in vitro
and in vivo. IFN- transcription was increased from as early as
3 dpi until at least 15 dpi, the time the experiment terminated.
There was also upregulation of interleukin-1 (IL-1), IFN-,
and, after 6 dpi, inducible nitric oxide synthase (iNOS). Xing
and Schat (64) proposed that IFN- plays a pivotal role in the
early pathogenesis and immune responses to MDV infection.
Recent progress in the cloning of additional chicken cyto-
kines has resulted in the development of a more comprehen-
sive panel of reagents for investigating the innate and acquired
immune mechanisms controlling responses to avian diseases,
at both cellular and molecular levels. This provides an oppor-
tunity to investigate the involvement of key cytokines in MD
pathogenesis in the context of resistant and susceptible chicken
genotypes. Chicken orthologues of the Th1 cytokines IFN-,
* Corresponding author. Mailing address: Institute for Animal
Health, Compton, Berkshire RG20 7NN, United Kingdom. Phone:
(44) 1635 577277. Fax: (44) 1635 577263. E-mail: pete.kaiser@bbsrc
.ac.uk.
† Present address: Bioproperties (Australia) Pty. Ltd., Ringwood
North, Victoria 3134, Australia.
762
IL-2, and IL-18 (18, 50, 56) and the proinflammatory cytokines
IL-1 (61) and IL-6 (51) have been cloned and sequenced.
IL-15 (37), which is closely related to IL-2, and the chemokine
IL-8 (5, 55) have also been cloned and sequenced. Genomic
sequences and gene structures for IFN- (28), IL-2 (26), IL-18
(Kaiser, unpublished data), IL-1 (Kaiser, unpublished data),
IL-15 (Kaiser, unpublished data), IL-8 (25), and IL-6 (Kaiser,
unpublished data) have been fully determined. This informa-
tion now makes it possible to design probes and primers to
specifically quantify cytokine mRNA by using real-time quan-
titative reverse transcription-PCR (RT-PCR), and so monitor
changes in cytokine transcription during the course of MD.
Experimental design and sample preparation. We deter-
mined MDV load and levels of the abovementioned cytokines
in spleen cells at various times after infection with MDV and
compared them with those in uninfected age-matched controls.
Differences in the levels of cytokine mRNA between resistant
and susceptible lines of birds during the course of MDV in-
fection should help delineate mechanisms underlying the re-
sistance/susceptibility profiles.
Chicks were obtained from four inbred lines of White Leg-
horns that were unvaccinated and maintained under disease-
free conditions at the Institute for Animal Health, Compton,
Berkshire, United Kingdom. At 2 weeks of age, chicks were
randomly selected and placed in “infected” and “control”
groups. Due to the need for contemporaneous sampling of
both control and infected chickens and comparisons between
the four inbred lines, the experiment was carried out in two
parts. The first involved only the MD-susceptible lines 72 and
P, and the second involved the MD-resistant lines 61 and N. In
each case, infected birds of both lines were housed in separate
cages in the same filtered-air, positive-pressure isolation room
and injected intra-abdominally with 1,000 PFU of the virulent
serotype 1 MDV strain HPRS-16 (46) in a chick kidney cell
(CKC) suspension (0.2 ml). Similarly, controls were kept to-
gether in a separate isolation room and injected intra-abdom-
inally with the same number of uninfected CKC (0.2 ml).
Spleens from three infected chickens and two controls of each
inbred line were removed at 3, 4, 5, 6, 7, 10, 14, 17, and 21 dpi.
Splenocytes were then purified by standard techniques, and
two samples of 106 cells were removed for DNA and RNA
extraction, respectively.
Quantification of viral load. MDV DNA was quantified with
TaqMan PCR. DNA was extracted by standard procedures,
and samples were stored at 20°C. The MDV-specific probe
(Table 1) was designed to be specific for the meq gene (24) and
TABLE 1. Real-time quantitative RT-PCR probes and primers
Target Probe orprimera Sequence
Exon
boundary Accession no.
b
meq Probe 5-(FAM)-AGACCCTGATGATCCGCATTGCGACT-(TAMRA)-3 M89471
F 5-GGTCTGGTGGTTTCCAGGTGA-3
R 5-GCATAGACGATGTGCTGCTGA-3
28S Probe 5-(FAM)-AGGACCGCTACGGACCTCCACCA-(TAMRA)-3 X59733
F 5-GGCGAAGCCAGAGGAAACT-3
R 5-GACGACCGATTTGCACGTC-3
IFN- Probe 5-(FAM)-TGGCCAAGCTCCCGATGAACGA-(TAMRA)-3 3/4 Y07922
F 5-GTGAAGAAGGTGAAAGATATCATGGA-3
R 5-GCTTTGCGCTGGATTCTCA-3
IL-1 Probe 5-(FAM)-CCACACTGCAGCTGGAGGAAGCC-(TAMRA)-3 5/6 AJ245728
F 5-GCTCTACATGTCGTGTGTGATGAG-3
R 5-TGTCGATGTCCCGCATGA-3
IL-2 Probe 5-(FAM)-ACTGAGACCCAGGAGTGCACCCAGC-(TAMRA)-3 2/3 AJ009800
F 5-TTGGAAAATATCAAGAACAAGATTCATC-3
R 5-TCCCAGGTAACACTGCAGAGTTT-3
IL-6 Probe 5-(FAM)-AGGAGAAATGCCTGACGAAGCTCTCCA-(TAMRA)-3 3/4 AJ250838
F 5-GCTCGCCGGCTTCGA-3
R 5-GGTAGGTCTGAAAGGCGAACAG-3
IL-8 Probe 5-(FAM)-TCTTTACCAGCGTCCTACCTTGCGACA-(TAMRA)-3 1/2 AJ009800
F 5-GCCCTCCTCCTGGTTTCAG-3
R 5-TGGCACCGCAGCTCATT-3
IL-15 Probe 5-(FAM)-AAGTTGCAAATCTTGCATTTCCATTTTTCCA-(TAMRA)-3 4/5 AJ416937
F 5-TAGGAAGCATGATGTACGGAACAT-3
R 5-TTTTTGCTGTTGTGGAATTCAACT-3
IL-18 Probe 5-(FAM)-CCGCGCCTTCAGCAGGGATG-(TAMRA)-3 4/5 AJ276026
F 5-AGGTGAAATCTGGCAGTGGAAT-3
R 5-ACCTGGACGCTGAATGCAA-3
a F, forward; R, reverse.
b Genomic DNA sequence.
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labeled with the fluorescent reporter dye 5-carboxyfluorescein
(FAM) at the 5 end and the quencher N, N, N, N-tetra-
methyl-6-carboxyrhodamine (TAMRA) at the 3 end. The
PCR assay used the TaqMan PCR core reagents kit (PE Ap-
plied Biosystems). Amplification and detection of specific
products were carried out with the ABI PRISM 7700 sequence
detection system (PE Applied Biosystems) with the following
cycle profile: 50°C for 2 min, 95°C for 10 min, and then 40
cycles of 95°C for 20 s and 60°C for 1 min.
A standard curve was prepared over a range of 10-fold
dilutions with comparable reaction efficiencies to estimate vi-
rus copy number from sample threshold cycle (Ct) values. The
method described by Pevenstein et al. (44) for absolute quan-
titation of varicella-zoster virus and herpes simplex virus was
followed, using a cloned 455-bp fragment of the MDV Eco Q
(meq) gene (24). Seven 10-fold serial dilutions of plasmid were
made, ranging from 57 101 to 5.7 107 copies of plasmid per
reaction. Each dilution was tested in duplicate. The plasmid
concentration in the undiluted miniprep sample was shown to
be 6.01  0.25 	g ml1 by spectrophotometry (optical density
at 260 nm [OD260]). With a molecular mass of 4.38  10
18 g
per plasmid, the undiluted plasmid preparation was calculated
to contain 1.37  0.06  1012 plasmids ml1. There are two
copies of the meq gene in the MDV genome, and therefore
virus copy number is assumed to be half the plasmid copy
number. Relevant standard curve data are shown in Table 2.
Statistical analysis of mean values between multiple groups
was done with one-way analysis of variance. When a level of
significance was found, a Tukey’s test was conducted on the
data to determine the relative difference between the means
within each data set. When there were only two groups of data,
means were compared by using a paired Student’s t test.
MDV was not detected by quantitative PCR assay in spleno-
cytes isolated from uninfected chicks (data not shown). There
were no significant differences in viral loads between the four
inbred lines until 10 dpi—the onset of latency (Fig. 1). Viral
loads in the two resistant lines were lower than those in the
susceptible lines from 10 dpi onwards, although because of
bird-to-bird variations, differences between the susceptible and
resistant lines were not significant (P 
 0.05) until after 10 dpi
for line N and 14 dpi for line 61. Of the two resistant lines, the
viral load in line 61 was greater (P 
 0.05) than that in line N
at 10 and 14 dpi and then decreased to the same level as that
in line N by 21 dpi.
To our knowledge, this is the first detailed comparison of
early changes in MDV copy number in spleen cells of chicken
genotypes that differ markedly in their resistance and mecha-
nisms of resistance to MD (2, 14, 49). In earlier studies, these
lines have been used in pairs: line N versus line P (1, 13, 20, 39)
and line 61 versus line 72 (3, 4, 32, 45). MD resistance in line N,
dependent on the B21 MHC haplotype, is highly protective
against clinical disease. Levels of MDV infection in the lym-
phoid organs during the lytic phase (first week postinfection)
are essentially indistinguishable between lines N and P (1, 13,
20, 39), although markedly reduced levels of latent infection
are evident in line N. Calnek (14) proposed that this MHC-
related genetic resistance, mainly expressed in the latent phase
of MD, has an immunological basis related to a lower level of
T-cell infection. By comparison, resistance in line 61 (B2 MHC
haplotype) is strongly associated with the MDV-1 locus (see
earlier). It has been postulated that resistance resides at the
level of target cell numbers and their susceptibility to MDV
infection and is evident during the lytic phase of infection (16,
32).
Bumstead et al. (10) reported that the correlation between
this PCR assay and plaque assays is high and suggested that
MDV copy number per cell is rather uniform. It therefore
seems reasonable to compare observations made in this study
TABLE 2. Standard curve data from real-time quantitative
RT-PCR of total RNA extracted from splenocytes
stimulated with mitogen or real-time quantitative
PCR of plasmid containing the meq gene
RNA
or
plasmid
Rna Log dilutions Ct valuesb R2c Slope
meqd 0.026 102–108 15–36 0.998 3.499
28S 0.05 101–105 8–22 0.9833 3.0005
IFN- 0.01 101–105 17–31 0.9899 3.289
IL-1 0.02 101–105 24–38 0.9856 3.1153
IL-2 0.02 101–105 26–38 0.9896 2.4279
IL-6 0.02 101–105 23–37 0.9992 3.2841
IL-8 0.02 101–105 14–27 0.9938 2.7728
IL-15 0.02 101–105 22–36 0.9952 2.8154
IL-18 0.02 101–105 17–33 0.9973 3.1123
a Rn, change in the reporter dye.
b Ct, threshold cycle value (the cycle at which the change in the reporter dye
levels detected passes the Rn).
c R2, coefficient of regression.
d meq, plasmid of known concentration containing the viral target sequence.
FIG. 1. Splenic MDV load at various times after infection with
MDV in four different inbred lines of chickens. MDV load was mea-
sured as MDV copy number per 106 leukocytes by quantitative PCR.
Each value is the mean of three samples, and vertical bars represent
the standard error of the mean. R, resistant; S, sensitive.
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with the PCR-based assay with earlier findings that used
plaque assays.
Both susceptible genotypes had higher viral loads than the
resistant lines from the onset of the latent phase (Fig. 1). These
markedly different patterns of viral load in splenocytes confirm
earlier findings that different resistance mechanisms must op-
erate in susceptible and resistant genotypes (reviewed by Ba-
con et al. [2] and Calnek [14]). Differences in splenocyte viral
loads in resistant lines from 10 dpi onwards are consistent with
the hypothesis that different mechanisms operate in MHC-
related and non-MHC-related MD resistance (2, 14). Spleno-
cyte MDV load in line N receded fairly rapidly in the early
latent phase, when MDV is found in latently infected T cells
(54), consistent with the suggestion (14) that specific cell-
mediated immune responses are an important component of
MHC-related resistance when cytotoxic T lymphocytes become
activated (41, 42). In contrast, the more gradual decrease in
splenocyte viral load in line 61 indicates different immunolog-
ical mechanisms are likely to be operating in non-MHC-
related resistance.
Quantification of cytokine mRNA expression. Cytokine
mRNA was isolated and the levels in infected and control
samples were quantified essentially as described by Kaiser et al.
(27). Total RNA was prepared from samples of purified
splenocytes from three infected birds and two uninfected birds
at each time point for each line by using the RNeasy mini kit
(Qiagen) and following the manufacturer’s instructions. Puri-
fied RNA was eluted in 140 	l of RNase-free water and stored
at 70°C. All cytokine probes were designed, from the se-
quence of the relevant genes, to lie across intron-exon bound-
aries (see Table 1 for details) and labeled with FAM at the 5
end and TAMRA at the 3 end. The RT-PCR assay used the
TaqMan EZ RT-PCR kit (PE Applied Biosystems). Amplifi-
cation and detection of specific products were also done with
the ABI PRISM 7700 Sequence Detection System, but with the
following cycle profile: 50°C for 2 min, 96°C for 5 min, 60°C for
30 min and 95°C for 5 min, followed by 40 cycles of 94°C for
20 s and 59°C for 1 min.
Standard curves for the cytokine and 28S rRNA-specific
reactions were generated as previously described (27). Rele-
vant standard curve data are shown in Table 2. To account for
variation in sampling and RNA preparation, the Ct values for
cytokine-specific product for each sample were standardized as
previously described (27).
There were no significant differences in expression of
mRNA for IL-1, IL-8, or IL-15, compared with the values for
the appropriate uninfected controls (data not shown). In-
creased levels of IL-2 in infected birds occurred only in line 72
at 21 dpi (data not shown). Increased levels of IFN- mRNA,
ranging from 5- to 25-fold, were evident in infected birds of all
lines between 3 and 10 dpi, except for line N, where differences
were evident at 3 to 7 dpi and at 21 dpi (Fig. 2). The greatest
increase was in line P, where IFN- mRNA levels increased
steadily from 5- to 25-fold between 3 and 7 dpi. Xing and Schat
(63) observed increased IFN- expression following MDV in-
fection from 3 to 15 dpi. Djeraba et al. (19) also reported
strong induction of IFN- mRNA expression in B21 haplotype
chickens at 3 and 7 dpi with a very virulent strain of MDV,
RB-1B. In this study, the extents of IFN-mRNA upregulation
were similar in all lines, with line P showing the greatest up-
regulation. The present work contrasts with an earlier study by
Hong and Sevoian (23) that reported IFN levels were higher in
resistant (K strain) than susceptible (S strain) chickens. How-
ever, Hong and Sevoian relied on a bioassay for IFNs that did
not differentiate IFN- from IFN-, IFN-, or IFN-/. Taken
together, the present results suggest that IFN- production is
unlikely to contribute to the differences in viral loads between
the resistant and susceptible inbred lines.
Xing and Schat (64) showed that IFN- has a negative effect
on lytic replication of MDV in cell culture. IFN- mRNA
levels peaked earlier in splenocytes from infected resistant
birds (4 dpi) than in those from infected susceptible birds (5 to
7 dpi). These early high levels of IFN- expression in resistant
lines could drive the virus into latency earlier during lytic
infection than in the susceptible lines. This would presumably
limit the level of latent infection and ultimately lead to a
reduction in clinical disease.
Marked differences between susceptible and resistant geno-
types were evident only for IL-6 (Fig. 3) and IL-18 (Fig. 4)
expression. Splenocytes from infected susceptible birds ex-
pressed high levels of IL-6 message (compared to uninfected
controls) early during MDV infection (3 to 5 dpi for line 72 and
4 and 5 dpi for line P). Splenocytes from infected birds of lines
61 and 72 both expressed high levels of IL-6 message at 10 and
21 dpi. For IL-18, splenocytes from infected susceptible birds
expressed high levels of message early during MDV infection
(4 and 5 dpi for both lines). Splenocytes from infected birds of
line 72 also expressed high levels of IL-18 message at 10 dpi.
Splenocytes from infected resistant lines never expressed more
IL-18 message than noninfected age-matched controls.
IL-6 is a proinflammatory cytokine, and its elevated produc-
tion early in cytolytic infection (Fig. 3) may simply represent a
response to increased pathology in susceptible lines, such as
line 72 (3). Xing and Schat (63) failed to detect any IL-6
expression following MDV infection. Unfortunately, these
FIG. 2. Quantification of IFN- in splenocytes after MDV infec-
tion, expressed as fold change in cytokine mRNA levels in infected
birds compared to those in age-matched, uninfected controls. Each
value is the mean of three samples, and vertical bars represent the
standard error. R, resistant; S, sensitive.
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workers quantified myelomonocytic growth factor (36) as a
measure of IL-6-like activity. Myelomonocytic growth factor is
an avian-specific cytokine that has homology with both mam-
malian IL-6 and granulocyte colony-stimulating factor (G-
CSF), but unlike IL-6, it does not have proinflammatory activ-
ity. The results therefore are not comparable with those for
chicken IL-6 (51) reported here.
IL-18 is a proinflammatory cytokine expressed by a wide
variety of cells, including monocytes/macrophages and den-
dritic cells. In mammals, IL-18 has three main roles: to induce
IFN- production (40), to enhance NK cell activity (58), and to
activate neutrophils (35). IL-18 is produced as a propeptide
that is cleaved into an active form by the action of caspase-1
(21, 22). It must therefore be borne in mind that expression of
IL-18 mRNA does not necessarily correlate with the expres-
sion of functional IL-18 protein. Assuming that IL-18 mRNA
is related, at least to some extent, to the production of bioac-
tive IL-18 and the kinetics of IFN- production following
MDV infection are broadly similar in resistant and susceptible
lines, the observed increase in IL-18 mRNA production early
in the lytic infection in susceptible lines is unlikely to have a
direct effect on IFN- expression.
Activation of NK cells after MDV has been implicated as an
important component of the cell-mediated immune response
in the genetically resistant line 61 (53). However, increased NK
activity was only detected in the late stages (28 to 35 dpi) of
MD indicating it is more likely to be involved in antitumor
responses than antiviral responses. Moreover, in line 72, NK
activity was actually reduced after MDV infection (52). The
increased levels of IL-18 in both susceptible lines in the present
study are therefore not consistent with it influencing NK ac-
tivity.
Xing and Schat (63) reported that IL-8 was expressed in
splenocytes from MDV-infected birds after 3 dpi. IL-8 can act
as a chemoattractant for T cells, among others. Moreover,
MDV has been shown to encode a CXC chemokine described
as a homologue of IL-8 (vIL-8) (43). This led Xing and Schat
(63) to speculate that the production of this CXC chemokine
during the lytic infection of B cells might attract T cells to the
areas of virus replication and, furthermore, that the observed
early expression of IFN- following MDV infection should
stimulate the expression of IL-8 receptors on T cells (cf. ref-
erence 57). There are several problems with this proposition.
First, we observed no evidence of MDV-induced changes in
chicken IL-8 expression in either resistant or susceptible lines.
More importantly, although vIL-8 has high amino acid identity
with human and chicken IL-8s, there are several important
differences between this so-called vIL-8 and known IL-8s. CXC
chemokines can be subdivided into two groups. Most possess
an ELR motif immediately preceding the first cysteine residue,
including IL-8. Other CXC chemokines, such as PF-4 and a
recently discovered B-lymphocyte chemoattractant, lack this
ELR motif (34). So-called “vIL-8” also lacks an ELR motif and
in its place has a DKR motif (43). The presence of the ELR
motif controls the tropism of the CXC chemokine, because
different CXC receptors bind CXC chemokines, depending on
the presence or absence of the ELR motif. In humans, the
genomic structure of most CXC chemokines consists of four
exons and three introns (including IL-8), whereas the genes for
PF-4 and NAP-2 comprise only three exons and two introns.
The gene encoding vIL-8 also has three exons and two introns.
Therefore the gene product should more properly be described
as a viral CXC chemokine (vCXC) rather than vIL-8.
Xing and Schat (63) also suggested that IFN- stimulates the
production of IL-1, which in turn upregulates IL-2 for the
generation of cytotoxic lymphocytes, and iNOS, which induces
macrophage nitric oxide (NO) production to inhibit MDV
replication. In contrast, we did not observe an increase in
IL-1 mRNA expression following MDV infection. However,
IL-1, like IL-18, is expressed as a propeptide and subse-
quently cleaved by caspase-1 (6, 30), so IL-1 mRNA does not
necessarily correlate with protein expression.
FIG. 3. Quantification of IL-6 in splenocytes after MDV infection,
expressed as fold change in cytokine mRNA levels in infected birds
compared to those in age-matched, uninfected controls. Each value is
the mean of three samples, and vertical bars represent the standard
error. R, resistant; S, sensitive.
FIG. 4. Quantification of IL-18 in splenocytes after MDV infec-
tion, expressed as fold change in cytokine mRNA levels in infected
birds compared to those in age-matched, uninfected controls. Each
value is the mean of three samples, and vertical bars represent the
standard error. R, resistant; S, sensitive.
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This work has shown differential IL-18 expression in spleen
cells of susceptible and resistant genotypes of chickens follow-
ing MDV infection. However, knowledge of the basic biology
of chicken IL-18 is very limited, and the functional relevance of
elevated IL-18 mRNA expression during the cytolytic phase of
infection in susceptible lines is difficult to account for at
present. As more reagents to study this cytokine become avail-
able, mechanisms underlying and controlled by elevated IL-18
mRNA expression should be elucidated. Recently, a number of
expressed sequence tags (ESTs) for chicken chemokines and
their receptors have become available. Considering the differ-
ent leukocyte classes involved in MD infection and the roles of
chemokines as chemoattractants for leukocytes, future studies
should provide further hypotheses to explain differences in
resistance to MD.
The results presented here show that, although MDV loads
in the two MDV-susceptible genotypes were similar, they dif-
fered markedly from those in resistant genotypes. More im-
portantly, the changes in MDV load differed between the two
resistant genotypes, consistent with the view that different im-
mune mechanisms operate in MHC-linked and non-MHC-
linked resistance (2, 14). These differences are almost certainly
driven by differences in cytokine expression in the different
inbred lines. There was increased expression of IFN- mRNA
after infection with MDV in all lines, confirming the view (48)
that this cytokine plays an important role in the immune re-
sponse to MDV. However, there were no differences in IFN-
mRNA levels between susceptible and resistant genotypes, but
there were marked differences in IL-6 and IL-18 mRNA levels,
indicating that these two cytokines could play a crucial role by
driving immune responses that in susceptible lines result in
tumor formation and in resistant lines result in lesion regres-
sion (11).
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